Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cancer of Stomach
- Chemotherapy Effect
- Complications, Postoperative
- Surgery- Complications
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapyMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is a prospective, multi-centers, open-label, single-arm study, and the aim of this trial is to evaluate the safety of laparoscopic distal D2 radical gastrectomy for the treatment of locally advanced gastric cancer (cT3-4a, N-/+, M0) after neoadjuvant chemotherapy.
This is a prospective, multi-centers, open-label, single-arm study, and the aim of this trial is to evaluate the safety of laparoscopic distal D2 radical gastrectomy for the treatment of locally advanced gastric cancer (cT3-4a, N-/+, M0) after neoadjuvant chemotherapy.
Tracking Information
- NCT #
- NCT03468712
- Collaborators
- Southern Medical University, China
- Beijing Cancer Hospital
- Shanghai Zhongshan Hospital
- Chinese PLA General Hospital
- Fujian Medical University Union Hospital
- The First Hospital of Jilin University
- Ruijin Hospital
- Southwest Hospital, China
- RenJi Hospital
- Sir Run Run Shaw Hospital
- The First Affiliated Hospital with Nanjing Medical University
- Guangdong Provincial People's Hospital
- Fudan University
- Harbin Medical University
- Tang-Du Hospital
- Investigators
- Principal Investigator: Jian-Kun Hu, M.D. Ph.D. West China Hospital
Get Well Soon